Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Hodgkin Disease × avelumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 2 Head and Neck Neoplasms 2 Gastrointestinal Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma, Merkel Cell 2 Breast Neoplasms 2 Urinary Bladder Neoplasms 1 Turcot syndrome 1 Stomach Neoplasms 1 Sarcoma 1 Penile Neoplasms 1 PD-L1 Positive Mutation Tumor 1 Non-Muscle Invasive Bladder Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Muscle Invasive Bladder Urothelial Carcinoma 1 Mesothelioma, Malignant 1 Melanoma 1 Leukemia, Myeloid, Chronic-Phase 1 Hodgkin Disease 1 Hemangiosarcoma 1 Glioblastoma 1 Esophageal Squamous Cell Carcinoma 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Hepatocellular 1 Carcinoma 1

Interventions

Cyclophosphamide 12 Etoposide 10 Brentuximab Vedotin 9 Doxorubicin 8 fludarabine phosphate 7 Vincristine 6 Vinblastine 6 Mycophenolic Acid 6 Melphalan 6 Dacarbazine 6 Bleomycin 6 Cyclosporine 5 camrelizumab 4 Rituximab 4 Radiotherapy 4 Peripheral Blood Stem Cell Transplantation 4 Nivolumab 4 Gemcitabine 4 Filgrastim 4 Decitabine 4 Cytarabine 4 Busulfan 4 Bendamustine Hydrochloride 4 pembrolizumab 3 Tacrolimus 3 Prednisone 3 Ifosfamide 3 Antilymphocyte Serum 3 fludarabine 2 Whole-Body Irradiation 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03617666 2023-12-12

AVENuE

University College, London

Phase 2 Unknown

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡